QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN (NYSE: QGEN) introduced IPA Investigator and the QIAGEN Discovery Platform to expand AI capabilities in research and drug discovery. IPA Investigator lets researchers ask questions in natural language, identify biological relationships and run analyses within QIAGEN Ingenuity Pathway Analysis, while examining the evidence behind results.
The company designed the QIAGEN Discovery Platform to support drug-target and biomarker identification, generate research hypotheses and automate parts of discovery. The offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights, whose bioinformatics tools are used by around 150,000 users.
QIAGEN (QGEN) received FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, completing its U.S. testing portfolio.
The new panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers in about one hour. A recently cleared panel for gram-positive bacteria and fungi covers 20 pathogen targets and 10 resistance markers. Together, the two panels cover 33 pathogen targets and 28 resistance markers, with both delivering results in about one hour. QIAstat-Dx combines sample preparation, multiplex PCR testing and data analysis in one automated workflow. More than 5,200 systems had been placed cumulatively as of the end of 2025.
QIAGEN (QGEN) launched QIAmini on September 24, 2026, an automated system for preparing small batches of research samples. The benchtop instrument processes up to eight samples per run and automates DNA and RNA extraction and purification. Across evaluated workflows, it reduced hands-on time by over 80% compared with manual sample processing.
QIAmini is QIAGEN’s third new sample preparation system launched in 2026, following systems for medium- and high-throughput work. Five dedicated kits support DNA and RNA processing from biological materials. QIAmini is intended for research use only, not for diagnostic procedures.
QIAGEN (QGEN) has called an Extraordinary General Meeting of Shareholders for November 6, 2026, at 2:00 p.m. CET in Venlo, the Netherlands. Shareholders will vote on appointing Jonathan M. Pratt to the Managing Board after his start as Chief Executive Officer on September 1, 2026. If approved, he will serve alongside Chief Financial Officer Roland Sackers as one of two Managing Board members. Shareholders will also vote on the discharge of former CEO Thierry Bernard for his service on the Managing Board through September 1, 2026. Meeting agenda, explanatory notes and related materials will be provided to shareholders and made available on QIAGEN’s Investor Relations website.
10x Genomics (Nasdaq: TXG) reported that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are licensed from Roche Sequencing Solutions. The jury upheld all three patents as valid and enforceable and awarded 10x Genomics over $4.8 million in damages, based on a 14% royalty rate on Parse’s U.S. sales of Evercode Whole Transcriptome products from February 2021 through June 30, 2026. According to 10x Genomics, it will seek enhanced damages, attorneys’ fees, and a permanent U.S. injunction against further infringement in post-trial proceedings.
QIAGEN (NYSE: QGEN) announced the commercial launch of QIAsymphony Connect, an IVD-compliant automation platform for clinical nucleic acid extraction. The system builds on the established QIAsymphony platform, which has more than 3,300 cumulative placements worldwide, and uses the same reagent kits and consumables to ease migration for existing users.
QIAsymphony Connect standardizes extraction across diverse molecular assay workflows, delivering highly concentrated DNA and RNA for downstream applications in liquid biopsy, oncology and infectious disease diagnostics. The platform processes up to 96 samples in four independent batches, offers complete sample traceability through barcode tracking and audit trails, and features integrated liquid handling and guided workflow setup to reduce hands-on time and variability.
According to QIAGEN, FDA listing in the U.S. and EUDAMED listing in Europe have been completed, and initial customer orders and early user feedback highlight improved usability, connectivity and workflow consistency.
QIAGEN (NYSE: QGEN) appointed Jonathan M. Pratt as Chief Executive Officer, effective September 1, 2026, succeeding Thierry Bernard. Pratt brings more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare, most recently as President and CEO of Filtration Group, which he led through its sale to Parker-Hannifin in August 2026.
According to QIAGEN, the Supervisory Board chose Pratt after a comprehensive search, citing his global industry knowledge and record of improving performance in analytical instruments, laboratory technologies and bioprocessing. He will also be proposed as a Managing Director at an Extraordinary General Meeting planned for the fourth quarter of 2026. Bernard will support an orderly transition through year-end.
QIAGEN reaffirmed its outlook for the third quarter and full-year 2026 and stated that its strategic review, supported by independent financial and legal advisors, remains ongoing. The company continues to target solid profitable growth and disciplined capital allocation.
QIAGEN (NYSE: QGEN) announced U.S. FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, its first QIAstat-Dx panel for bloodstream infections. The test detects 20 gram-positive bacterial and fungal pathogen targets, a broad pan gram-negative target and 10 genetic antimicrobial resistance markers from positive blood cultures in about one hour.
The clearance marks QIAGEN’s entry into U.S. bloodstream infection testing and adds a fourth major infectious disease area to the QIAstat-Dx syndromic platform, which is available in more than 100 countries with over 5,200 cumulative placements as of end-2025. QIAGEN is also pursuing FDA review of a complementary QIAstat-Dx BCID GN Plus AMR Panel focused on gram-negative pathogens.
QIAGEN (NYSE: QGEN) reported Q2 2026 net sales of $535 million, unchanged from Q2 2025 on a reported and constant exchange rate (CER) basis, but ahead of an outlook for about a 2% CER decline. Growth pillars delivered about 5% CER sales growth, led by Sample technologies, QIAcuity and QIAGEN Digital Insights, while QuantiFERON rose 1% CER and QIAstat-Dx faced a tough comparison in respiratory testing.
The adjusted operating income margin was 29.4%, with diluted EPS of $0.50 and adjusted diluted EPS of $0.62, above the outlook for at least $0.60 CER. Operating cash flow reached $301 million in H1 2026, and QIAGEN reaffirmed its full-year 2026 outlook for net sales growth of about 1–2% CER and adjusted diluted EPS of at least $2.43 CER. The company also highlighted a 40% dividend increase versus 2025 and ongoing investments following the Parse acquisition.
QIAGEN (NYSE: QGEN) is highlighting its molecular testing portfolio as U.S. cyclosporiasis cases climb above 1,600 confirmed since May 2026, with another 7,000 potential cases under investigation. Health authorities are tracking multiple outbreaks of Cyclospora cayetanensis, a foodborne parasite not detectable by routine stool culture.
According to QIAGEN, its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 detects Cyclospora within about an hour as part of a 16-target gastrointestinal menu. For research and public health applications, QIAGEN offers a Cyclospora digital PCR assay for the QIAcuity system and the PulseNet-approved QIAseq FX DNA Library Prep Kit to support shotgun NGS workflows for identifying and characterizing foodborne pathogens.